🎗️ Melanoma — 2026-W44

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Five-year update of the randomized phase 2-3 RELATIVITY-047 trial in advanced melanoma, published in Nature Medicine. Confirms durable progression-free and overall survival benefit of adding relatlimab to nivolumab with consistent safety, and explores LAG-3-related biomarkers.

Phase 1 dose-escalation trial of CD20-targeting CAR T-cells in refractory advanced melanoma, published in Eur J Cancer. Dose-limiting toxicities appeared at the higher dose and activity was minimal, so it remains investigational with no practice change.

Preclinical translational study in BRAF V600E melanoma models, published in Nature Communications. Suggests p38α inhibition may restore sensitivity to PD-1 blockade, but this remains hypothesis-generating without clinical testing.